Dusse Fabian, Edayadiyil-Dudásova Michaela, Thielmann Matthias, Wendt Daniel, Kahlert Philipp, Demircioglu Ender, Jakob Heinz, Schaefer Simon T, Pilarczyk Kevin
Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center Essen, University Hospital Essen, Hufelandstraße 55, 45122, Essen, Germany.
Department of Anesthesiology and Intensive Care Medicine, Medical Center Cologne-Merheim, University of Witten/Herdecke, Ostmerheimerstrasse 200, 51109, Cologne, Germany.
BMC Anesthesiol. 2016 Sep 8;16:76. doi: 10.1186/s12871-016-0244-8.
Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) leading to increased mortality and morbidity. Urinary G1 cell cycle arrest proteins TIMP-2 and IGFBP7 have recently been suggested as sensitive biomarkers for early detection of AKI in critically ill patients. However, the precise role of urinary TIMP-2 and IGFBP7 in patients undergoing TAVI is unknown.
In a prospective observational trial, 40 patients undergoing TAVI (either transaortic or transapical) were enrolled. Serial measurements of TIMP-2 and IGFBP7 were performed in the early post interventional course. The primary clinical endpoint was the occurrence of AKI stage 2/3 according to the KDIGO classification.
Now we show, that ROC analyses of [TIMP-2][IGFBP7] on day one after TAVI reveals a sensitivity of 100 % and a specificity of 90 % for predicting AKI 2/3 (AUC 0.971, 95 % CI 0.914-1.0, SE 0.0299, p = 0.001, cut-off 1.03). In contrast, preoperative and postoperative serum creatinine levels as well as glomerular filtration rate (GFR) and perioperative change in GFR did not show any association with the development of AKI. Furthermore, [TIMP-2][IGFBP7] remained stable in patients with AKI ≤1, but its levels increased significantly as early as 24 h after TAVI in patients who developed AKI 2/3 in the further course (4.77 ± 3.21 vs. 0.48 ± 0.68, p = 0.022). Mean patients age was 81.2 ± 5.6 years, 16 patients were male (40.0 %). 35 patients underwent transapical and five patients transaortic TAVI. 15 patients (37.5 %) developed any kind of AKI; eight patients (20 %) met the primary endpoint and seven patients required renal replacement therapy (RRT) within 72 h after surgery.
Early elevation of urinary cell cycle arrest biomarkers after TAVI is associated with the development of postoperative AKI. [TIMP-2]*[IGFBP7] provides an excellent diagnostic accuracy in the prediction of AKI that is superior to that of serum creatinine.
急性肾损伤(AKI)是经导管主动脉瓣植入术(TAVI)后常见的并发症,会导致死亡率和发病率上升。尿G1细胞周期停滞蛋白TIMP-2和IGFBP7最近被认为是危重症患者早期检测AKI的敏感生物标志物。然而,尿TIMP-2和IGFBP7在接受TAVI治疗的患者中的具体作用尚不清楚。
在一项前瞻性观察性试验中,纳入了40例接受TAVI(经主动脉或经心尖)治疗的患者。在介入治疗后的早期阶段对TIMP-2和IGFBP7进行连续测量。主要临床终点是根据KDIGO分类标准出现2/3期AKI。
现在我们发现,TAVI术后第1天对[TIMP-2][IGFBP7]进行ROC分析显示,预测AKI 2/3的敏感性为100%,特异性为90%(AUC 0.971,95%CI 0.914-1.0,SE 0.0299,p = 0.001,临界值1.03)。相比之下,术前和术后血清肌酐水平、肾小球滤过率(GFR)以及围手术期GFR的变化与AKI的发生均无关联。此外,AKI≤1期患者的[TIMP-2][IGFBP7]保持稳定,但在后续发展为AKI 2/3期的患者中,其水平在TAVI后24小时就显著升高(4.77±3.21 vs. 0.48±0.68,p = 0.022)。患者平均年龄为81.2±5.6岁,16例为男性(40.0%)。35例患者接受经心尖TAVI,5例患者接受经主动脉TAVI。15例患者(37.5%)发生了任何类型的AKI;8例患者(20%)达到主要终点,7例患者在术后72小时内需要肾脏替代治疗(RRT)。
TAVI后尿细胞周期停滞生物标志物的早期升高与术后AKI的发生相关。[TIMP-2]*[IGFBP7]在预测AKI方面具有出色的诊断准确性,优于血清肌酐。